Results 161 to 170 of about 283,312 (250)

Current status and future perspectives of platelet function‐guided precision antiplatelet therapy for patients with cerebral infarction

Neuroprotection, EarlyView.
Antiplatelet agents target the cyclooxygenase‐1 (COX‐1)/thromboxane A2 (TXA2) and adenosine diphosphate (ADP)‐P2Y12 (cytochrome P450 2C19 [CYP2C19]‐metabolized) platelet activation pathways, resulting in either drug resistance or over‐inhibition. The individualized therapeutic window balances ischemic risk (triggered by high on‐treatment platelet ...
Guoliang Zhu, Xiaoling Chen, Xinyi Huang, Quandan Tan, Qing Cao, Yali Yang, Yapeng Lin, Jie Yang   +7 more
wiley   +1 more source

Inactivation of interleukin-15 reduces spontaneous atherosclerosis in <i>apolipoprotein E</i>-deficient mice. [PDF]

Front Physiol
Dadoo O, Sokeechand BSH, Lee A, Fuller MT, Wang YCD, MacDonald ME, Batenburg NL, Igdoura SA, Richards CD, Ashkar AA, Trigatti BL.   +10 more
europepmc   +1 more source

Clinical interpretation of cardiac troponin in athletes: From endurance exercise to exertional injury

PM&R, EarlyView.
Abstract Exertional heat illness (EHI) and exertional rhabdomyolysis (ER) are increasingly recognized causes of morbidity in competitive and tactical athletes. Cardiac troponin (cTn) elevation, traditionally viewed as a marker of myocardial necrosis, may also be seen in these settings and can create significant diagnostic and prognostic uncertainty ...
John‐Henry L. Dean, Jeffrey C. Leggit, M. Alaric Franzos   +2 more
wiley   +1 more source

Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice. [PDF]

Aging Cell
de Mol J, de Korte DH, Depuydt MAC, Smit V, Kleijn MNAB, van Santbrink PJ, Binder CJ, Porsch F, Schaftenaar FH, Foks AC.   +9 more
europepmc   +1 more source

Bioactive Natural Products in Cardiovascular Disease: Focus on Thrombotic Events

Phytotherapy Research, EarlyView.
An overview of the role of natural products (NP) in cardiovascular disease prevention, highlighting key mechanisms of action: including antiplatelet, antithrombotic, anti‐inflammatory, and antioxidant effects. Additionally, it illustrates the integration of diet–drug interactions, nutritional epigenetics, and the role of artificial intelligence in ...
Maria Nektaria Magkoulia, Despoina Pantazi   +1 more
wiley   +1 more source

FAP-Directed CAR-NKT Cells for Multi-Target Suppression of Atherosclerotic Progression. [PDF]

Circ Res
Zhu E, Li YR, Cho JM, Kropp R, Zhang Y, Sanaiha Y, Kwon OJ, Zhu Y, Park SK, Arianpour B, Justo M, Zhao P, Wang S, Gu M, Benharash P, Yang L, Hsiai TK.   +16 more
europepmc   +1 more source

Protosappanin A Alleviates Atherosclerosis by Regulating the MDM2/GPX4 Axis‐Mediated Endothelial Ferroptosis

Phytotherapy Research, EarlyView.
PTA alleviates atherosclerosis by regulating the MDM2/GPX4 axis‐mediated endothelial ferroptosis. ABSTRACT Endothelial ferroptosis is a crucial pathogenic driver of atherosclerosis (AS) progression. Protosappanin A (PTA), a bioactive compound from Caesalpinia sappan L., protects cardiovascular vessels by regulating ferroptosis.
Jiamei Fu, Lin Zhu, Wenwei Yang, Mengnan Li, Zhixin Wu, Shude Sun, Yabin Zhou   +6 more
wiley   +1 more source

CD80 as an Important Immune Mediator and Therapeutic Target in Atherosclerosis. [PDF]

Int J Mol Sci
Blagov A, Vatlin A, Borodko D, Maksaeva A.   +3 more
europepmc   +1 more source

Potential of Ginkgo biloba Extract to Intervene in Chronic Inflammation‐Related Diseases

Phytotherapy Research, EarlyView.
Chronic inflammation is a pathological mechanism underpinning many diseases. Ginkgo biloba extract (GBE) is well known for its anti‐inflammatory property. GBE and its active constituents have been shown to attenuate pro‐inflammatory cytokine production, suppress nuclear factor kappa B activation, restore redox homeostasis, and modulate disease‐relevant
Yipeng Lin, Inho Cho, Xue Zhu, Ke Wang, Ling Zhu, Wenchang Wong, Michael Murray, Fanfan Zhou   +7 more
wiley   +1 more source

Clinical utility of lipoprotein(a) and the ApoB/ApoA-I ratio in the risk assessment of acute coronary syndrome: from single biomarkers to integrated risk stratification. [PDF]

Front Cardiovasc Med
Lu Z, Li P, Li R, Guo X, Li S, Wang J.
europepmc   +1 more source